RecruitingNCT07054073

HCMR Re-Imaging Study


Sponsor

Christopher Kramer

Enrollment

314 participants

Start Date

Mar 30, 2026

Study Type

OBSERVATIONAL

Conditions

Summary

This study aims to learn what might predict heart problems (like sudden death from a fast heart rhythm or heart failure) in people with a genetic condition called hypertrophic cardiomyopathy (HCM). HCM causes the heart muscle to become thick, which can make the heart stiff and harder to work properly. It can also affect the heart's electrical system. This study is looking to enroll patients that were previously part of a research project called "HCMR - Novel Predictors of Outcome in Hypertrophic Cardiomyopathy." The results of that study are still being reviewed, but they might show that people who had a substance called Gadolinium (MRI contrast or dye) collected in their heart muscle may have a higher risk for heart problems, including sudden cardiac death. This is called "late gadolinium enhancement" (LGE). This study is aiming to do follow-up imaging on those patients to better understand how LGE affects people with HCM.


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Inclusion Criteria12

  • Patients in the original HCMR cohort with:
  • Obstructive HCM
  • Males and females between 18 and 65 years of age
  • BMI \< 35 kg/m2
  • LVOT-G at entry as follows:
  • Resting gradient ≥50 mmHg OR Resting gradient ≥30 mmHg and \<50 mmHg with post-Valsalva LVOT-G ≥50 mmHg
  • • NYHA Class II or III or
  • Non-obstructive HCM
  • Same criteria as above except resting LVOT-G is \<30mmHg and post-Valsalva gradient \<50mm Hg
  • BMI \<40kg/m2
  • Elevated NT-proBNP \> 300 pg/mL at the time of enrollment
  • LVEF ≥55%

Exclusion Criteria5

  • Paroxysmal atrial fibrillation or flutter documented prior to entry.
  • Paroxysmal or permanent atrial fibrillation requiring rhythm restoring treatment (eg, direct-current cardioversion, ablation procedure, or antiarrhythmic therapy) ≤6 months prior to entry. (This exclusion does not apply if atrial fibrillation has been treated with anticoagulation and adequately rate-controlled for \>6 months.)
  • History of syncope or sustained ventricular tachyarrhythmia with exercise within 6 months prior to entry.
  • Pregnancy due to potential risk of gadolinium to the fetus
  • Patients with a pacemaker that are pacer-dependent as they cannot undergo MRI

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERNone - observational study

None - observational study


Locations(8)

Northwestern

Evanston, Illinois, United States

Brigham & Women's Hospital

Boston, Massachusetts, United States

Tufts Medical Center

Medford, Massachusetts, United States

University of Michigan

Ann Arbor, Michigan, United States

Cleveland Clinic

Cleveland, Ohio, United States

University of Virginia

Charlottesville, Virginia, United States

University Hospitals Birmingham NHS Foundation Trust

Birmingham, United Kingdom

London Chest Hospital

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07054073


Related Trials